Europe Inhaled Nitric Oxide Market Size study, by Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome, Others), and Country Forecasts 2022-2032

Europe Inhaled Nitric Oxide Market Size study, by Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome, Others), and Country Forecasts 2022-2032

Europe Inhaled Nitric Oxide Market is valued approximately at USD 269.11 million in 2023 and is anticipated to grow with a healthy growth rate of more than 7.19% over the forecast period 2024-2032. Inhaled nitric oxide (iNO) is a medicinal gas used to improve oxygenation in individuals facing specific respiratory challenges. It works by expanding blood vessels in the lungs, leading to increased blood flow in crucial areas for effective oxygen exchange. Nitric oxide is naturally present in the body, aiding in vasodilation and blood pressure control. iNO specifically targets blood vessels around oxygen-rich lung regions, encouraging relaxation and improved blood flow to enhance oxygen uptake by red blood cells. This targeted approach is vital in treating conditions like neonatal respiratory distress syndrome, chronic obstructive pulmonary disease, acute respiratory distress syndrome, among others. iNO plays a vital role in managing vascular and oxygenation issues, especially in neonatal and critical care scenarios. The increasing number of collaboration and research initiatives between academic institutions, research groups, and pharmaceutical businesses is a key trend that is supporting the growth of the Europe Inhaled Nitric Oxide Market. These programs aim to increase the range of indications for iNO usage in respiratory care while also improving treatment results.

The growth of the Inhaled Nitric Oxide (iNO) market is driven by the expansion and modernization of healthcare infrastructure, which play crucial roles in enhancing market opportunities. iNO therapy is gaining significant recognition for its therapeutic advantages in respiratory and cardiovascular conditions, especially in cases such as neonatal hypoxic respiratory failure and pulmonary hypertension. The improved healthcare infrastructure has increased accessibility to advanced medical technologies, including iNO delivery systems. With hospitals and healthcare facilities equipped with advanced infrastructure, they can administer iNO therapy promptly and efficiently, leading to better patient outcomes. Additionally, the strong clinical research and regulatory approvals, rising awareness campaigns and increasing population drive the growth of the Europe Inhaled Nitric Oxide Market. Continual clinical research and robust evidence validating the effectiveness of iNO therapy for diverse respiratory conditions are driving its growing adoption in clinical settings throughout Europe. This adoption is further bolstered by supportive regulatory frameworks and approvals from agencies such as the European Medicines Agency (EMA), ensuring the safety and efficacy of iNO products. These measures instill confidence among healthcare providers and patients, encouraging broader utilization of iNO therapy across the region. However, stringent application norms across various regions, along with high costs incurred with the procedure is expected to hinder the market growth between 2022 and 2032.

The key countries considered for the Europe Inhaled Nitric Oxide Market study includes UK, Germany, France, Italy, Spain, and Rest of Europe. In 2023, Germany was the largest market with the highest number of market shares because the region has a significant burden of respiratory diseases such as asthma, COPD, and pulmonary hypertension. The increasing prevalence of these conditions drives the demand for effective treatments like iNO therapy. Along with this, increasing government policies & reimbursement, rising emphasis on the on neonatal care, and growing number of awareness campaigns and educational initiatives about respiratory diseases and available treatments, including iNO therapy, drive patient and provider awareness and adoption in Germany. The market in UK, on the other hand, is expected to develop at the fastest rate over the forecast period.

Major market player included in this report are:
Air Liquide Healthcare (France)
SOL Group (Italy)
Merck KGaA (Germany)
Mallinckrodt Pharmaceuticals (United Kingdom)
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Application
Neonatal Respiratory Treatment
Chronic Obstructive Pulmonary Disease
Acute Respiratory Distress Syndrome
Others
By Region:
Europe
UK
Germany
France
Spain
Italy
ROE

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.